GIP/GLP-1 & amylin agonists × body weight & composition

TrialDiabetes, obesity & metabolism2022

A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.

Kenichi Furihata et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2022

Randomised comparison

Probably lowered body weight & composition

−1.60percentage points−1.90 to −1.20

As reported

difference −1.60 %, 95% CI −1.90 to −1.20

One number in the abstract

the abstract, start to end

versus placebo at 8 weeks in HbA1c up to 1.6% (95% CI 1.2%-1.9%; P < .0001

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−1.60−1.90 to −1.20
GIP/GLP-1 & amylin agonistsBody weight & composition

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

36 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 34647404